文献速递肿瘤 PET/CT核素与放射性配体治疗

[18F]Di-PyL的种间生物分布差异与PET显像性能:一种靶向前列腺特异性膜抗原的二聚体PET显像剂用于前列腺癌

Interspecies Variability in Biodistribution and PET Imaging Performance of [18F]Di-PyL: A Dimeric, PSMA-Targeted PET Agent for Prostate Cancer.
PubMed 文献 · J Nucl Med · 2025-08-01

研究开发了基于[18F]DCFPyL结构的二聚体PSMA靶向示踪剂[18F]Di-PyL,在小鼠、猪、犬和食蟹猴中系统评估生物分布后再进行人体初步显像。结果显示其PSMA结合亲和力较[18F]DCFPyL高23倍,各物种肾脏摄取最高但分布模式存在种间差异,前列腺癌患者PET/CT中骨转移灶显像对比度优良。

要点

  • [18F]Di-PyL的PSMA结合亲和力较[18F]DCFPyL高23倍。
  • 各物种肾脏摄取最高,但肺、心、唾液腺、椎骨和肝脾摄取模式存在种间差异。
  • 前列腺癌患者PET/CT显示肿瘤定位强、骨转移灶对比度优良。

核心结论

  • [18F]Di-PyL是一种有前景的PSMA PET示踪剂,具有增强的结合亲和力及优良的体外和体内性能。
  • 跨物种[18F]Di-PyL PET研究显示显著的生物分布变异性,但一致突显了该示踪剂优越的PSMA靶向能力。
  • 这些发现为后续临床前动物研究提供了关键数据,并为后续临床试验奠定了坚实基础。

研究设计与样本

  • 开发了基于[18F]DCFPyL结构的二聚体PSMA靶向放射性示踪剂[18F]Di-PyL。
  • 系统评估了[18F]Di-PyL在小鼠、猪、犬和食蟹猴中的生物分布,随后进行了人体初步显像研究。
  • 比较分析旨在提供该二聚体示踪剂种间生物分布和显像性能的关键信息。

主要发现

  • [18F]Di-PyL的PSMA结合亲和力较[18F]DCFPyL高23倍。
  • 体外实验显示[18F]Di-PyL在PSMA阳性细胞中细胞摄取增加。
  • 生物分布研究显示显著种间差异,所有物种中肾脏摄取最高。
  • 比格犬和猪的肺和心脏观察到独特摄取模式,食蟹猴唾液腺和椎骨高摄取。
  • 人体中肝脏和脾脏观察到显著摄取,前列腺癌患者PET/CT显示骨转移灶肿瘤定位强、对比度优良。

关键数值与推荐

  • [18F]Di-PyL的PSMA结合亲和力较[18F]DCFPyL高23倍。
  • 所有评估物种中肾脏摄取最高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate cancer (PCa) is a leading cause of cancer deaths, making effective early detection, precise staging, and monitoring of biochemical recurrence crucial. Next-generation prostate-specific membrane antigen (PSMA) PET tracers could detect small or early metastatic lesion, especially in patients with low prostate-specific antigen. However, species differences in PSMA expression affect tracer biodistribution and imaging performance, highlighting the need for cross-species studies to optimize design and ensure clinical accuracy. Methods: We developed [18F]Di-PyL, a dimeric, PSMA-targeted radiotracer based on the structure of [18F]DCFPyL, and systematically evaluated the biodistribution of [18F]Di-PyL in mice, pigs, dogs, and cynomolgus monkeys before conducting a preliminary imaging study in humans. The aim of these comparative analyses was to provide critical insights into the interspecies biodistribution and imaging performance of this dimeric agent, while highlighting its potential to improve the detection of PCa, particularly in patients with low prostate-specific antigen levels and biochemical recurrence. Results: [18F]Di-PyL showed a 23-fold higher PSMA-binding affinity than did [18F]DCFPyL. In vitro assays showed increased cellular uptake of [18F]Di-PyL in PSMA-positive cells. Biodistribution studies revealed significant interspecies differences, with the kidneys showing the highest uptake across all species. Distinct uptake patterns were observed in the lungs and hearts of beagles and pigs, whereas cynomolgus monkeys exhibited high uptake in salivary glands and vertebrae. In humans, significant uptake was noted in the liver and spleen. PET/CT imaging in patients with PCa revealed strong tumor localization and excellent contrast in bone metastases. Conclusion: [18F]Di-PyL is a promising PSMA PET tracer with enhanced binding affinity and excellent performance in vitro and in vivo. [18F]Di-PyL PET studies across species revealed significant biodistribution variability but consistently highlighted the tracer's superior PSMA-targeting capability. These findings provide critical data to support further preclinical animal studies and lay a solid foundation for subsequent clinical trials.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Chen Y, Zhang X, Wang X, et al. Interspecies Variability in Biodistribution and PET Imaging Performance of [18F]Di-PyL: A Dimeric, PSMA-Targeted PET Agent for Prostate Cancer. J Nucl Med. 2025. PMID: 40675754. doi:10.2967/jnumed.125.270069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。